A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Trial Profile

A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Vismodegib (Primary) ; Ethinylestradiol; Norethisterone; Rosiglitazone
  • Indications Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 29 Nov 2012 New source identified and integtrated: (M.D. Anderson Cancer Center: 2010-0472).
    • 25 Aug 2011 Status changed from recruiting to active, no longer recruiting.
    • 23 Nov 2010 Status changed from not yet recruiting to recruiting, according to the Barbara Ann Karmanos Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top